nodes	percent_of_prediction	percent_of_DWPC	metapath
Baclofen—GABBR2—midbrain—Gilles de la Tourette syndrome	0.197	0.222	CbGeAlD
Baclofen—GABBR2—nervous system—Gilles de la Tourette syndrome	0.162	0.182	CbGeAlD
Baclofen—GABBR2—central nervous system—Gilles de la Tourette syndrome	0.156	0.175	CbGeAlD
Baclofen—GABBR2—brain—Gilles de la Tourette syndrome	0.124	0.139	CbGeAlD
Baclofen—GABBR1—midbrain—Gilles de la Tourette syndrome	0.0995	0.112	CbGeAlD
Baclofen—GABBR1—brain—Gilles de la Tourette syndrome	0.0625	0.0703	CbGeAlD
Baclofen—SLC22A8—nervous system—Gilles de la Tourette syndrome	0.0323	0.0363	CbGeAlD
Baclofen—SLC22A8—central nervous system—Gilles de la Tourette syndrome	0.0311	0.035	CbGeAlD
Baclofen—SLC22A8—brain—Gilles de la Tourette syndrome	0.0247	0.0278	CbGeAlD
Baclofen—GABBR2—Transmission across Chemical Synapses—SLC6A3—Gilles de la Tourette syndrome	0.00679	0.0615	CbGpPWpGaD
Baclofen—GABBR2—G alpha (i) signalling events—DRD3—Gilles de la Tourette syndrome	0.00649	0.0588	CbGpPWpGaD
Baclofen—GABBR2—G alpha (i) signalling events—DRD4—Gilles de la Tourette syndrome	0.0063	0.057	CbGpPWpGaD
Baclofen—GABBR2—G alpha (i) signalling events—DRD2—Gilles de la Tourette syndrome	0.00587	0.0531	CbGpPWpGaD
Baclofen—GABBR2—Neuronal System—SLC6A3—Gilles de la Tourette syndrome	0.0052	0.0471	CbGpPWpGaD
Baclofen—GABBR1—Transmission across Chemical Synapses—SLC6A3—Gilles de la Tourette syndrome	0.00438	0.0396	CbGpPWpGaD
Baclofen—GABBR1—G alpha (i) signalling events—DRD3—Gilles de la Tourette syndrome	0.00418	0.0379	CbGpPWpGaD
Baclofen—GABBR1—G alpha (i) signalling events—DRD4—Gilles de la Tourette syndrome	0.00406	0.0368	CbGpPWpGaD
Baclofen—GABBR2—GPCR ligand binding—DRD3—Gilles de la Tourette syndrome	0.00393	0.0356	CbGpPWpGaD
Baclofen—GABBR2—GPCR ligand binding—DRD4—Gilles de la Tourette syndrome	0.00381	0.0345	CbGpPWpGaD
Baclofen—GABBR1—G alpha (i) signalling events—DRD2—Gilles de la Tourette syndrome	0.00378	0.0342	CbGpPWpGaD
Baclofen—SLC22A8—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC6A3—Gilles de la Tourette syndrome	0.00358	0.0325	CbGpPWpGaD
Baclofen—GABBR2—GPCR ligand binding—DRD2—Gilles de la Tourette syndrome	0.00355	0.0322	CbGpPWpGaD
Baclofen—GABBR1—Neuronal System—SLC6A3—Gilles de la Tourette syndrome	0.00335	0.0304	CbGpPWpGaD
Baclofen—GABBR1—GPCR ligand binding—DRD3—Gilles de la Tourette syndrome	0.00253	0.0229	CbGpPWpGaD
Baclofen—GABBR2—GPCR ligand binding—HTR2A—Gilles de la Tourette syndrome	0.00249	0.0225	CbGpPWpGaD
Baclofen—GABBR1—GPCR ligand binding—DRD4—Gilles de la Tourette syndrome	0.00246	0.0223	CbGpPWpGaD
Baclofen—GABBR1—GPCR ligand binding—DRD2—Gilles de la Tourette syndrome	0.00229	0.0207	CbGpPWpGaD
Baclofen—GABBR2—GPCR downstream signaling—DRD3—Gilles de la Tourette syndrome	0.00222	0.0201	CbGpPWpGaD
Baclofen—GABBR2—GPCR downstream signaling—DRD4—Gilles de la Tourette syndrome	0.00215	0.0195	CbGpPWpGaD
Baclofen—GABBR2—Signaling by GPCR—DRD3—Gilles de la Tourette syndrome	0.00202	0.0183	CbGpPWpGaD
Baclofen—GABBR2—GPCR downstream signaling—DRD2—Gilles de la Tourette syndrome	0.00201	0.0182	CbGpPWpGaD
Baclofen—GABBR2—Signaling by GPCR—DRD4—Gilles de la Tourette syndrome	0.00196	0.0177	CbGpPWpGaD
Baclofen—GABBR2—Signaling by GPCR—DRD2—Gilles de la Tourette syndrome	0.00182	0.0165	CbGpPWpGaD
Baclofen—SLC22A8—SLC-mediated transmembrane transport—SLC6A3—Gilles de la Tourette syndrome	0.00163	0.0148	CbGpPWpGaD
Baclofen—GABBR1—GPCR ligand binding—HTR2A—Gilles de la Tourette syndrome	0.0016	0.0145	CbGpPWpGaD
Baclofen—GABBR1—GPCR downstream signaling—DRD3—Gilles de la Tourette syndrome	0.00143	0.013	CbGpPWpGaD
Baclofen—GABBR2—GPCR downstream signaling—HTR2A—Gilles de la Tourette syndrome	0.00141	0.0127	CbGpPWpGaD
Baclofen—GABBR1—GPCR downstream signaling—DRD4—Gilles de la Tourette syndrome	0.00139	0.0126	CbGpPWpGaD
Baclofen—GABBR1—Signaling by GPCR—DRD3—Gilles de la Tourette syndrome	0.0013	0.0118	CbGpPWpGaD
Baclofen—GABBR1—GPCR downstream signaling—DRD2—Gilles de la Tourette syndrome	0.00129	0.0117	CbGpPWpGaD
Baclofen—GABBR2—Signaling by GPCR—HTR2A—Gilles de la Tourette syndrome	0.00128	0.0116	CbGpPWpGaD
Baclofen—GABBR1—Signaling by GPCR—DRD4—Gilles de la Tourette syndrome	0.00126	0.0114	CbGpPWpGaD
Baclofen—GABBR2—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	0.00119	0.0108	CbGpPWpGaD
Baclofen—GABBR1—Signaling by GPCR—DRD2—Gilles de la Tourette syndrome	0.00117	0.0106	CbGpPWpGaD
Baclofen—GABBR2—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	0.00116	0.0105	CbGpPWpGaD
Baclofen—GABBR2—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	0.00108	0.00975	CbGpPWpGaD
Baclofen—GABBR1—GPCR downstream signaling—HTR2A—Gilles de la Tourette syndrome	0.000906	0.00821	CbGpPWpGaD
Baclofen—SLC22A8—Transmembrane transport of small molecules—SLC6A3—Gilles de la Tourette syndrome	0.000828	0.0075	CbGpPWpGaD
Baclofen—GABBR1—Signaling by GPCR—HTR2A—Gilles de la Tourette syndrome	0.000823	0.00745	CbGpPWpGaD
Baclofen—GABBR1—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	0.000767	0.00695	CbGpPWpGaD
Baclofen—GABBR2—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	0.000754	0.00683	CbGpPWpGaD
Baclofen—GABBR1—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	0.000745	0.00675	CbGpPWpGaD
Baclofen—GABBR1—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	0.000694	0.00628	CbGpPWpGaD
Baclofen—GABBR1—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	0.000486	0.0044	CbGpPWpGaD
